A Selective Class of Inhibitors for the CLC-Ka Chloride Ion Channel
Total Page:16
File Type:pdf, Size:1020Kb
A selective class of inhibitors for the CLC-Ka chloride ion channel Anna K. Kostera,b,1, Chase A. P. Woodb,1, Rhiannon Thomas-Trana, Tanmay S. Chavanb, Jonas Almqvistc, Kee-Hyun Choid, J. Du Boisa,2, and Merritt Madukeb,2 aDepartment of Chemistry, Stanford University, Stanford, CA 94305; bDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305; cDepartment of Cell and Molecular Biology, Uppsala University, 751 24 Uppsala, Sweden; and dMaterials and Life Science Research Division, Korea Institute of Science and Technology, 02792 Seoul, Republic of Korea Edited by Richard W. Aldrich, The University of Texas at Austin, Austin, TX, and approved March 21, 2018 (received for review December 7, 2017) CLC proteins are a ubiquitously expressed family of chloride- without intervention, permanent neurological damage can occur (20, selective ion channels and transporters. A dearth of pharmacolog- 21). Selectivity between small molecule inhibitors of CLC-Ka and ical tools for modulating CLC gating and ion conduction limits CLC-Kb is critical for any clinical application, as these two channels investigations aimed at understanding CLC structure/function and are also expressed in the inner ear, where they play critical but re- physiology. Herein, we describe the design, synthesis, and evalu- dundant roles: disruption of both homologs results in deafness, while ation of a collection of N-arylated benzimidazole derivatives (BIMs), disruption of either individually has no effect on hearing (22). one of which (BIM1) shows unparalleled (>20-fold) selectivity for CLC- The development of selective small molecules that specifically Ka over CLC-Kb, the two most closely related human CLC homologs. target either CLC-Ka or CLC-Kb poses a formidable challenge in Computational docking to a CLC-Ka homology model has identified a ligand design due to the >90% sequence identity between the two BIM1 binding site on the extracellular face of the protein near the homologs. Prior reports of CLC inhibitors largely describe low- chloride permeation pathway in a region previously identified as a affinity (midmicromolar to millimolar IC50) compounds that lack binding site for other less selective inhibitors. Results from site- selectivity. The most potent CLC inhibitor known is a peptide directed mutagenesis experiments are consistent with predictions of toxin, GaTx2, which selectively inhibits CLC-2 with an IC50 of this docking model. The residue at position 68 is 1 of only ∼20 extra- ∼20 pM. However, despite its potency, GaTx2 inhibition saturates cellular residues that differ between CLC-Ka and CLC-Kb. Mutation of at ∼50% (23), thus limiting its use as a pharmacological probe. this residue in CLC-Ka and CLC-Kb (N68D and D68N, respectively) Accordingly, we have been motivated to identify small molecule reverses the preference of BIM1 for CLC-Ka over CLC-Kb, thus show- inhibitors of specific CLCs. Two classes of small molecule inhibi- ing the critical role of residue 68 in establishing BIM1 selectivity. Mo- tors have been reported to display moderate potency and selectivity lecular docking studies together with results from structure–activity forCLC-KaoverCLC-Kb.Thefirst, a collection of stilbene relationship studies with 19 BIM derivatives give insight into the in- disulfonates, is a promiscuous class of anion transport inhibitors creased selectivity of BIM1 compared with other inhibitors and iden- (24–26). One of these, 4,4′-diisothiocyano-2,2′-stilbenedisulfonic tify strategies for further developing this class of compounds. acid (DIDS), was used as a chemical tool to corroborate the dimeric architecture of the Torpedo CLC-0 channel (27). Sub- chloride channel | molecular probes | electrophysiology sequently, our laboratories showed that DIDS hydrolyzes in − LC proteins are a class of highly selective chloride (Cl ) ion Significance Cchannels and transporters that are essential for proper physiological function, including electrical signaling in muscles Chloride ion channels and transporters (CLCs) are critical to car- and neurons and regulation of ion homeostasis (1–4). CLCs diovascular, neurological, and musculoskeletal function. Small possess a unique homodimeric, double-barreled structure and molecules capable of selectively inhibiting CLCs would serve as operate through distinct gating (opening/closing) mechanisms valuable tools for investigating CLC function and would have po- (5–10), which differ markedly from those of sodium, potassium, tential applications for treating CLC-related disorders. The lack of and calcium channels. While researchers in the field have made such agents has impeded efforts to study this family of proteins. important progress toward understanding general CLC structural This work introduces a class of inhibitors with unprecedented se- dynamics and physiology, achieving a precise mechanistic un- lectivity for a single CLC homolog, CLC-Ka. Insights gained through derstanding of these processes has remained a challenge (11–13). experiments to validate a predicted ligand binding site and to Small molecules that bind and modulate specific CLC homologs evaluate structure–activity relationships rationalize inhibitor po- could serve as valuable tools for untangling the complex gating tency and CLC-Ka selectivity. Our findings provide tools for studies behaviors and diverse physiological functions within the CLC of CLC-Ka function and will assist subsequent efforts to advance family. Small molecule modulators of CLCs also hold promise as specific molecular probes for different CLC homologs. therapeutic leads (14, 15). For certain kidney-related disorders, two Author contributions: A.K.K., C.A.P.W., J.A., K.-H.C., J.D.B., and M.M. designed research; CLC homologs, CLC-Ka and CLC-Kb, are particularly compelling A.K.K., C.A.P.W., R.T.-T., T.S.C., J.A., and K.-H.C. performed research; A.K.K., C.A.P.W., targets due to their important roles in maintaining electrolyte R.T.-T., T.S.C., J.A., K.-H.C., J.D.B., and M.M. analyzed data; and A.K.K., J.D.B., and M.M. balance. In humans, CLC-Kb loss-of-function mutations result in wrote the paper with contributions from all authors. type III Bartter’s syndrome, a salt-wasting disorder characterized The authors declare no conflict of interest. by low blood pressure (16). This phenotype suggests CLC-Kb as This article is a PNAS Direct Submission. a potential target for antihypertensive therapeutics. Similarly, Published under the PNAS license. − mouse KO models show that CLC-Ka Cl transport is necessary See Commentary on page 5311. for concentration of urine (17, 18) and thus suggest that inhibitors 1A.K.K. and C.A.P.W. contributed equally to this work. could be used to treat hyponatremia (19), a condition in which 2To whom correspondence may be addressed. Email: [email protected] or maduke@ blood concentrations of sodium are low. Hyponatremia develops stanford.edu. when the kidneys fail to excrete water efficiently and can occur in This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. patients with heart failure, cirrhosis, renal failure, or other condi- 1073/pnas.1720584115/-/DCSupplemental. tions (19, 20). Treatment of hyponatremia can be challenging, and Published online April 18, 2018. E4900–E4909 | PNAS | vol. 115 | no. 21 www.pnas.org/cgi/doi/10.1073/pnas.1720584115 Downloaded by guest on September 23, 2021 NH buffer solution to form polythiourea oligomers, which are more NO2 NO2 2 t KO Bu Fe/FeCl3 SEE COMMENTARY potent antagonists of CLC-0, CLC-Ka, and CLC-ec1 than DIDS Cl F Cl NH Cl NH DMF, 0 °C HOAc itself (28). A DIDS pentamer (Fig. 1A) is the most potent and NH Cl Cl 2 EtOH, 70 °C selective nonpeptidic CLC inhibitor known, with an IC50 against Cl CLC-Ka of 0.5 μM and ∼100-fold increased IC50 against CLC- Kb (28). However, structure–activity relationship (SAR) studies NH and further development of DIDS-based inhibitors are severely 2 N N CS2, KOH 30% H2O2 hampered due to the low water solubility of these oligomeric SH SO3 K Cl NH N N Cl Cl Cl Cl molecules as well as the synthetic challenges of systematically Cl EtOH, H2O 1 M KOH modifying the DIDS scaffold. A second class of CLC inhibitors 70 °C MeOH isbasedonanaryl-substitutedbenzofurancarboxylicacid(29, 30). The most notable of these compounds, MT-189 and SRA- Scheme 1. Synthesis of BIMs. 36 (Fig. 1B), are ∼10-fold less potent than the DIDS pentamer but more amenable to synthetic manipulation. While SRA- 36 inhibits both CLC-Ka and CLC-Kb with equal potency, MT- BIM1 Exhibits Enhanced Homolog Selectivity. CLC-K channels were 189 has a nearly threefold greater apparent affinity for CLC-Ka expressed in Xenopus oocytes, and two-electrode voltage clamp (TEVC) recording was used to measure currents before and over CLC-Kb (IC50 = 7vs.20μM) (29). after perfusion of inhibitor solutions. At 100 μM, BIM1 is an Results and Discussion effective inhibitor of CLC-Ka but shows markedly reduced ac- Inhibitor Design and Synthesis. Our design of N-arylated benz- tivity toward CLC-Kb (Fig. 2 A and B and Table S1). The IC50 ± μ imidazole derivatives (BIMs) follows from previous reports by for BIM1 against CLC-Ka, 8.5 0.4 M, is similar to that ± μ Liantonio et al. (29, 30) that describe the inhibitory effects of reported for MT-189 (7.0 1.0 M) (29). In contrast, the po- benzofuran carboxylate compounds against CLC-Ka and CLC- tency of BIM1 against CLC-Kb is significantly diminished [IC50 = 200 ± 20 μM for BIM1 (Fig. 2C) vs. 20 ± 2 μM for MT- Kb (29, 30). In these studies, the most potent CLC-K biaryl in- > hibitors were found to be conformationally restricted molecules 189 (29)]. The identification of BIM1, which displays 20-fold selectivity for CLC-Ka over CLC-Kb, is notable given that these that favor a twisted, noncoplanar structure of the two aromatic ∼ rings (Fig.